Researchers of The Schepens Eye Research Institute of Massachusetts Eye and Ear in Boston and the Harvard Medical School ophthalmology department have conducted a study that shows Ranibizumab as a promising prevention of proliferative vitreoretinopathy.
Ranibizumab is an anti-VEGF-A monoclonal antibody fragment that reduces the bioactivity of vitreous and prevents the development of PVR.
The National Eye Institute of NIH, Canadian Institute of Health Research, Department of Defense and Massachusetts Lions Foundation funded the study.
More Articles on Ophthalmology:
NovaBay Pharmaceuticals Begins Patient Trial of Pink-Eye Treatment
FDA Approves PROLENSA from Bausch + Lomb
LENSAR Laser System Earns FDA 510(k) Clearance
Ranibizumab is an anti-VEGF-A monoclonal antibody fragment that reduces the bioactivity of vitreous and prevents the development of PVR.
The National Eye Institute of NIH, Canadian Institute of Health Research, Department of Defense and Massachusetts Lions Foundation funded the study.
More Articles on Ophthalmology:
NovaBay Pharmaceuticals Begins Patient Trial of Pink-Eye Treatment
FDA Approves PROLENSA from Bausch + Lomb
LENSAR Laser System Earns FDA 510(k) Clearance